Iwona Grygoruk, *Grzegorz Helbig, Anna Kopińska, Katarzyna Wiśniewska-Piąty, Małgorzata Krawczyk-Kuliś, Sławomira Kyrcz-Krzemień
Trzecie autologiczne przeszczepienie hematopoetycznych komórek krwiotwórczych jako konsolidacja remisji u chorych ze szpiczakiem plazmocytowym – analiza jednoośrodkowa
Third autologous hematopoietic stem cell transplantation (AHSCT) as a remission consolidation in multiple myeloma – single centre experience
Department of Hematology and Bone Marrow Transplantation, Silesian Medical University, Katowice
Head of Department: prof. Sławomira Kyrcz-Krzemień, MD, PhD
Multiple myeloma (MM) is a recurrent and incurable neoplasm of B-cell origin. MM accounts for about 10% of all hematological malignancies and it is characterized by a clonal proliferation of atypical plasma cells producing monoclonal protein, mostly IgG (1). A median overall survival (OS) was ~ 3-5 years and at least very good partial response (VGPR) rate was 10%, when “older” therapeutic schema e.g. VAD (vincristine, adriamycin, dexamethasone) were used in clinical practice (2). The introduction of novel agents such immunomodulators and proteasome inhibitor resulted in a significant increase of complete remission (CR) rate as well as OS (3, 4, 5). High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) remains a standard therapeutic procedure for younger MM patients (< 65-70 years) without significant co-morbidities. Particular benefit of AHSCT was observed for patients transplanted in CR after induction chemotherapy (6). A double AHSCT is offered for a small proportion of MM patients, but this procedure is reserved only for patients who did not achieve at least VGPR after a single transplant (7). The safety and efficacy of the 3rd AHSCT requires further studies due to a low number of patients receiving such procedure so far. Herein, we report on the results of the 3rd AHSCT for recurrent, chemo-sensitive MM patients.
1. Kyle RA, Rajkumar SV: Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9.
2. Harousseau JL, Attal M, Avet-Loiseau H et al.: Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologus stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010; 28: 4621-9.
3. Cavo M, Rajkumar SV, Palumbo A et al.: International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologus stem cell transplantation. Blood 2011; 117: 6063-73.
4. Dingli D, Rajkumar SV: How best to use new therapies in multiple myeloma. Blood Rev 2010; 24: 91-100.
5. Rajkumar SV: Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8: 479-91.
6. Haas R, Bruns I, Kobbe G, Fenk R: High-dose therapy and autologous peripheral stem cell transplantation in patients with multiple myeloma. Recent Results Cancer Res 2011; 183: 207-38.
7. Kumar A, Kharfan MA, Glasmacher A, Djulbegovic B: Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 2009; 101: 100-106.
8. Blade J, Samson D, Reece D et al.: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood Marrow Transplant. Brit J Haematol 1998; 102: 1115-1123.
9. Greipp PR, San Migel J, Durie BG et al.: International staging system for multiple myeloma. J Clin Oncol. 2005; 23: 3412-3420.
10. Giralt S: Stem cell transplantation for multiple myeloma: current and future status. Hematology Am Soc Hematol Educ Program 2011; 2011: 191-6.
11. Koreth J, Cutler CS, Djulbegovic B et al.: High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma. A systemic review and meta analysis of randomized controlled trials. Biol Blood Marrow 2007; 13: 183-96.
12. Harousseau JL, Attal M, Avet-Loiseau H: The role of complete response in multiple myeloma. Blood. 2009; 114: 3139-3146.
13. Chanan-Khan, Giraltt S: Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010; 28: 2612-2624.
14. Sonneveld P, Schmidt-Wolf IGH, van der Holt B: HORON-65/ /GMMG-HD 4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan and maintenance with patient with newly diagnosed MM (abstract). Blood 2010; 116 Abs. 40.
15. Wang M, Giralt S, Delasalle K et al.: Borezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 2007; 12: 235-239.
16. Neben K, Lokhorst HM, Jauch A et al.: Administration of bortezomib before and after autologous stem-cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012; 119: 940-8.
17. Avet-Loiseau H, Leleu X, Roussel M et al.: Bortezomib plus dexamethasone induction improves outcome of patients with t(4:14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010; 28: 4630-4634.
18. Attal M, Harousseau JL, Facon T et al.: Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-502.
19. Cavo M, Tosi P, Zamagni E et al.: Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007; 25: 2434-41.
20. Putkonen M, Rauhala A, Hala M et al.: Double versus single autotransplantation in myeloma; a single center experience of 100 patients. Haematologica 2005; 90: 562-3.
21. Jourdan E, Blaise D, Fegueux N et al.: Third autologous stem cell transplants for late of multiple myeloma. Bone Marrow Transplant 1996; 17: 885-886.
